EUVIMEDEUVIMED entdecken
Crossref

Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT)

Yasamin Yousefi, Reza Nejati, Atiye Eslahi, Farzaneh Alizadeh, Shima Farrokhi, Ahmad Asoodeh, Majid Mojarrad

Journal of Neuro-Oncology · 2024

DOI: 10.1007/s11060-024-04708-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Yasamin Yousefi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Temozolomide, Antineoplastic Agents, Alkylating, CRISPR-Cas Systems, Down-Regulation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Glioblastoma (GBM) stands out as the most prevalent and aggressive intracranial tumor, notorious for its poor prognosis. The current standard-of-care for GBM patients involves surgical resection followed by radiotherapy, combined with concurrent and adjuvant chemotherapy using Temozolomide (TMZ). The effectiveness of TMZ primarily relies on the activity of O6-methylguanine DNA methyltransferase (MGMT), which removes alkyl adducts from the O6 position of guanine at the DNA level, thereby counteracting the toxic effects of TMZ. METHOD: In this study, we employed fusions of catalytically-inactive Cas9 (dCas9) to DNA methyltransferases (dCas9-DNMT3A) to selectively downregulation MGMT transcription by inducing methylation at MGMT promoter and K-M enhancer. RESULT: Our findings demonstrate a significant reduction in MGMT expression, leading to intensified TMZ sensitivity in the HEK293T cell line. CONCLUSION: This study serves as a proof of concept for the utilization of CRISPR-based gene suppression to overcome TMZ resistance and enhance the lethal effect of TMZ in glioblastoma tumor cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideAntineoplastic Agents, AlkylatingCRISPR-Cas SystemsDown-RegulationGlioblastomaHumansDNA Repair EnzymesBrain NeoplasmsDNA Modification MethylasesTumor Suppressor ProteinsHEK293 CellsDrug Resistance, NeoplasmDNA MethylationGene Expression Regulation, NeoplasticCell Line, TumorPromoter Regions, Genetic

Stichwörter der Autor:innen

CRISPR-dCas9GlioblastomaMGMTTMZ

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingDNA Repair EnzymesDNA Modification MethylasesTumor Suppressor ProteinsMGMT protein, human

Autor:innen und Institutionen

  • Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Department of Pathology, Fox Chase Cancer Center, Temple University Health System, 19111, Philadelphia, PA, USA.
  • Department of chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. Asoodeh@um.ac.ir.
  • Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. mojaradm@mums.ac.ir.

Zitieren

APA

Yousefi, Y., Nejati, R., Eslahi, A., Alizadeh, F., Farrokhi, S., Asoodeh, A., & Mojarrad, M. (2024). Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT). Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04708-0

Vancouver

Yousefi Y, Nejati R, Eslahi A, Alizadeh F, Farrokhi S, Asoodeh A, et al. Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT). Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04708-0

BibTeX
@article{Yousefi2024,
  author = {Yousefi, Yasamin and Nejati, Reza and Eslahi, Atiye and Alizadeh, Farzaneh and Farrokhi, Shima and Asoodeh, Ahmad and Mojarrad, Majid},
  title = {Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT)},
  journal = {Journal of Neuro-Oncology},
  year = {2024},
  doi = {10.1007/s11060-024-04708-0}
}
Kostenlos starten →